CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 5,421	$ 4,237
Marketable securities, current	1,391	2,113
Receivables	6,300	5,543
Inventories	1,166	1,241
Prepaid expenses and other	576	570
Total Current Assets	14,854	13,704
Property, plant and equipment	5,001	4,980
Goodwill	6,863	6,875
Other intangible assets	1,210	1,385
Deferred income taxes	1,610	2,996
Marketable securities, noncurrent	2,480	2,719
Other assets	1,533	1,048
Total Assets	33,551	33,707
Current Liabilities:
Short-term debt obligations	987	992
Accounts payable	2,248	1,664
Accrued liabilities	6,014	5,271
Deferred income, current	83	762
Income taxes payable, current	231	152
Total Current Liabilities	9,563	8,841
Deferred income, noncurrent	454	547
Income taxes payable, noncurrent	3,548	973
Pension and other liabilities	1,164	1,283
Long-term debt	6,975	5,716
Total Liabilities	21,704	17,360
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,070 in 2017 and 4,129 in 2016, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2017 and 2016	221	221
Capital in excess of par value of stock	1,898	1,725
Accumulated other comprehensive loss	(2,289)	(2,503)
Retained earnings	31,160	33,513
Less cost of treasury stock - 575 million common shares in 2017 and 536 million in 2016	(19,249)	(16,779)
Total Bristol-Myers Squibb Company Shareholders' Equity	11,741	16,177
Noncontrolling interest	106	170
Total Equity	11,847	16,347
Total Liabilities and Equity	$ 33,551	$ 33,707